<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="154624">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01796691</url>
  </required_header>
  <id_info>
    <org_study_id>BOCLAplan02</org_study_id>
    <secondary_id>[Ruhr-University Bochum]</secondary_id>
    <nct_id>NCT01796691</nct_id>
  </id_info>
  <brief_title>The Bochum Optimizing Clopidogrel-Aspirin Therapy and MORTality Study (BOCLA-Mort)</brief_title>
  <acronym>BOCLA-Mort</acronym>
  <official_title>Optimized Antiplatelet Therapy With Aspirin and Clopidogrel Improves Mortality Compared to Standard Treatment.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ruhr University of Bochum</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ruhr University of Bochum</source>
  <oversight_info>
    <authority>Germany: Ethics Commission</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comparing standard treatment versus optimized antiplatelet therapy and outcomes measures.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is aimed to evaluate if optimized antiplatelet treatment using a test and treat
      algorithm (with whole blood aggregometry) is able to improve clinical outcome of patients
      compared to standard treatment without platelet function testing.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case Control, Time Perspective: Retrospective</study_design>
  <primary_outcome>
    <measure>Adverse cardiac events (MACE: mortality,rehospitalisation,myocardial infarction)</measure>
    <time_frame>Follow up for up to 12 months (retrospective analysis)</time_frame>
    <safety_issue>No</safety_issue>
    <description>MACE-rate</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">600</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Standard therapy</arm_group_label>
    <description>Antiplatelet therapy following coronary stenting without platelet function testing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Optimized antiplatelet therapy</arm_group_label>
    <description>Platelet function testing and according to a test and treat strategy improve the antiplatelet therapy in low-responder.
Treatment adjustments were done as published before - see BOCLA-Plan manuscript. (Reference: Tailored antiplatelet therapy can overcome clopidogrel and aspirin resistance--the BOchum CLopidogrel and Aspirin Plan (BOCLA-Plan) to improve antiplatelet therapy. BMC Med. 2011 Jan 12;9:3.)</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients following coronary stenting if informed consent was obtained
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  coronary stent implantation

        Exclusion Criteria:

          -  no consent
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Horst Neubauer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ruhr-University Bochum, Cardiovascular Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cardiovascular Center, Ruhr-University Bochum</name>
      <address>
        <city>Bochum</city>
        <state>NRW</state>
        <zip>D-44791</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Neubauer H, Kaiser AF, Endres HG, Krüger JC, Engelhardt A, Lask S, Pepinghege F, Kusber A, Mügge A. Tailored antiplatelet therapy can overcome clopidogrel and aspirin resistance--the BOchum CLopidogrel and Aspirin Plan (BOCLA-Plan) to improve antiplatelet therapy. BMC Med. 2011 Jan 12;9:3. doi: 10.1186/1741-7015-9-3.</citation>
    <PMID>21226927</PMID>
  </reference>
  <reference>
    <citation>Neubauer H, Lask S, Engelhardt A, Mügge A. How to optimise clopidogrel therapy? Reducing the low-response incidence by aggregometry-guided therapy modification. Thromb Haemost. 2008 Feb;99(2):357-62.</citation>
    <PMID>18278186</PMID>
  </reference>
  <reference>
    <citation>Siller-Matula JM, Francesconi M, Dechant C, Jilma B, Maurer G, Delle-Karth G, Gouya G, Ruzicka K, Podczeck-Schweighofer A, Christ G. Personalized antiplatelet treatment after percutaneous coronary intervention: The MADONNA study. Int J Cardiol. 2012 May 30. [Epub ahead of print]</citation>
    <PMID>22656044</PMID>
  </reference>
  <verification_date>February 2013</verification_date>
  <lastchanged_date>February 24, 2013</lastchanged_date>
  <firstreceived_date>February 17, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ruhr University of Bochum</investigator_affiliation>
    <investigator_full_name>Horst Neubauer</investigator_full_name>
    <investigator_title>PHD, MD</investigator_title>
  </responsible_party>
  <keyword>Clopidogrel</keyword>
  <keyword>aspirin</keyword>
  <keyword>low response</keyword>
  <keyword>platelet aggregation</keyword>
  <keyword>Acute Coronary Syndrome</keyword>
  <keyword>Coronary Stent Implantation</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
